Mylan Laboratories, parent company of Mylan Bertek Pharma in RTP, is acquiring a majority interest in King Pharmaceuticals in a deal worth $4 billion.
The acquisition was announced early Monday morning.
Mylan is acquiring some 56 percent interest in King.
